Page 1

February 4 , 2021 BD Announces First Fiscal Quarter Results ; Raises Fiscal 2021 Guidance - First fiscal quarter revenues of $ 5.315 billion grew 25.8 % on a reported basis . On a currency- neutral basis , revenues increased 24.3 % . - BD's COVID - 19 testing sales of $ 867 million contributed 20.5 percentage points to revenue growth on a reported basis . This includes BD Veritor ™ Plus System revenues of $ 688 million . - First fiscal quarter GAAP diluted earnings per share ( EPS ) increased 285 % year - over - year to $ 3.35 . - Adjusted EPS increased 71.7 % year - over - year to $ 4.55 . - BD is updating its fiscal 2021 guidance , including raising its fiscal 2021 adjusted EPS guidance to $ 12.75- $ 12.85 . FRANKLIN LAKES , N.J. , Feb. 4 , 2021 / PRNewswire / -- BD ( Becton , Dickinson and Company ) ( NYSE : BDX ) , a leading global medical technology company , today reported quarterly revenues of $ 5.315 billion for the first fiscal quarter ended December 31 , 2020. This represents an increase of 25.8 % over the prior - year period on a reported basis and was primarily driven by the contribution of BD's COVID - 19 diagnostic revenues , which totaled $ 867 million , contributing 20.5 percentage points to the company's total reported revenue growth in the quarter . On a currency - neutral basis , revenues increased 24.3 % . " BD's strong revenue and EPS growth reflect solid execution across the company and positive momentum to start fiscal 2021 , " said Tom Polen , CEO and president of BD . " While the market continues to be dynamic with the COVID - 19 pandemic , BD has emerged as an essential partner to help the world respond to the COVID - 19 pandemic from diagnostics to devices used in treatment to injection devices for vaccines and real - time surveillance and reporting . I'm proud of the worldwide BD team for their COVID - 19 response efforts and support of healthcare providers around the world . We are focused on driving our BD 2025 Grow - Simplify - Empower strategic initiatives which include bringing new and exciting innovations to the health care markets , expanding access globally and creating value for our shareholders . To that end , we continue to make solid progress . " First Fiscal Quarter 2021 Operating Results As reported , diluted EPS for the first fiscal quarter were $ 3.35 , compared with $ 0.87 in the prior - year period , which represents an increase of 285.1 % . Adjusted diluted EPS were $ 4.55 , compared with $ 2.65 in the prior - year period , which represents an increase of 71.7 % , or 73.6 % on a currency - neutral basis . Segment Results In the BD Medical segment , worldwide revenues for the first fiscal quarter of $ 2.261 billion increased 8.2 % versus the prior - year period on a reported basis and 6.9 % on a currency - neutral basis driven by growth from all four business units . Growth in our Medication Delivery Solutions and Medication Management Solutions business units reflect solid execution as well as higher patient acuity and increased demand for products and solutions used in the treatment and prevention of COVID - 19 . In addition , continued demand for our pre - fillable syringe portfolio drove continued strength in the Pharmaceutical Systems unit . Revenue growth in Diabetes Care reflects the benefit of the timing of orders in the U.S. as well as an easier comparison to the prior year . In the BD Life Sciences segment , worldwide revenues for the quarter of $ 1.979 billion increased 76.2 % over the prior - year period as reported , or 74.1 % on a currency - neutral basis . COVID - 19 diagnostic revenues were $ 867 million , which includes BD Veritor TM Plus System revenues of $ 688 million , with the remaining revenues related to the BD Max ™ COVID- 19 tests and specimen collection and transport . There was continued improvement in routine diagnostic testing and specimen collection as procedure volumes recovered but remained below pre - COVID levels . As expected , revenues in the Biosciences unit declined , as the continued recovery in research and clinical lab activity and the benefit from COVID - 19 vaccine research was more than offset by a difficult comparison from the prior year benefit of licensing revenues . In the BD Interventional segment , worldwide revenues for the quarter of $ 1.075 billion increased 6.2 % over the prior - year period as reported and 5.0 % on a currency - neutral basis . The segment's performance reflects greater resiliency in both elective and routine outpatient procedure volumes in the U.S. in the Surgery and Peripheral Intervention business units . Volumes also benefited from practitioners working through their patient backlog during the quarter . Within the Surgery unit , strong growth in infection prevention was offset by ongoing headwinds related to lower procedures due to the pandemic . In